Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates

Journal of Medicinal Chemistry

Volumn 48, Issue 16, 2005, Pages 5349-5359

  Otvos Jr , Laszlo ^a,b   Wade, John D ^c   Lin, Feng ^c   Condie, Barry A ^b   Hanrieder, Joerg ^d   Hoffmann, Ralf ^d  

^a OLPE LLC   (United States)

^b WISTAR INSTITUTE   (United States)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLPROLYLASPARTYLLYSYLPROLYLARGINYLPROLYLTYROSYLLEUCYLPROLYLTHREONYLPRO LYLPROLYLPROLYLARGINYLPROLYLVALYLTYROSYLASPARAGINYLARGININE; CIPROFLOXACIN; PEPTIDE DERIVATIVE; PROLINE; PROTEIN DNAK; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; DERIVATIZATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG STABILITY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; URINARY TRACT INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL AVAILABILITY; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG RESISTANCE, BACTERIAL; DRUG STABILITY; ESCHERICHIA COLI; FLUOROQUINOLONES; INSECT PROTEINS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PROLINE; SALMONELLA TYPHIMURIUM; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 23644459481     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050347i     Document Type: Article

References (60)

1. Overbye, K. M.; Barrett JF. Antibiotics: where did we go wrong? Drug Discovery Today 2005, 10, 45-52.
2. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 2004, 10, S122-129.
3. Dan, M. The use of fluoroquinolones in gonorrhea: the increasing problem of resistance. Expert Opin. Pharmacother. 2004, 5, 829-854.
4. Alos, J. I.; Serrano, M. G.; Gomez-Garces, J. L.; Perianes, J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin. Microbiol. Infect. 2005, 11, 199-203.
5. Hooton, T. M.; Besser, R.; Foxman, B.; Fritsche, T. R.; Nicolle, L. E. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin. Infect. Dis. 2004, 39, 75-80.
6. st century. Clin. Microbiol. Infect. 2004, 10 Suppl. 4, 10-17.
7. Bush, K.; Macielag, M.; Weidner-Wells, M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr. Opin. Microbiol. 2004, 7, 466-476.
8. Ge, Y.; MacDonald, D. L.; Holroyd, K. J.; Thornsberry, C.; Wexler, H.; Zasloff, M. In vitro properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 1999, 43, 782-788.
9. Hancock, R. E. W.; Scott, M. G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8856-8861.
10. Bower, M. A.; Cudic, M.; Campbell, W.; Wade, J. D.; Otvos, L., Jr. Walking the fine line between intracellular and membrane activities of antibacterial peptides. Lett. Pept. Sci. 2003, 10, 463-473.
11. Chen, Y.; Mant, C. T.; Farmer, S. W.; Hancock, R. E.; Vasil, M. L.; Hodges, R. S. Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 2005, 280, 12316-12329.
12. Loffet, A. Peptides as drugs: is there a market? J. Pept. Sci. 2002, 8, 1-7.
13. Cudic, M.; Otvos, L., Jr. Intracellular targets of antibacterial peptides. Curr. Drug Targets 2002, 3, 101-106.
14. Park, C. B.; Kim, H. S.; Kim, S. C. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 1998, 244, 253-257.
15. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B. A.; Hoffmann, R.; Otvos, L., Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001, 40, 3016-3026.
16. Kragol, G.; Hoffmann, R.; Chattergoon, M. A.; Lovas, S.; Cudic, M.; Bulet, P.; Condie, B. A.; Rosengren, K. J.; Montaner, L. J.; Otvos, L., Jr. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur. J. Biochem. 2002, 269, 4226-4237.
17. Bencivengo, A.-M.; Cudic, M.; Hoffmann, R.; Otvos, L., Jr. The efficacy of the antibacterial peptide, pyrrhocoricin, is finely regulated by its amino acid residues and active domains. Lett. Pept. Sci. 2001, 8, 201-209.
18. Casteels, P.; Romagnolo, J.; Castle, M.; Casteels-Josson, K.; Erdjument-Bromage, H.; Tempst, P. Biodiversity of apidaecin-type peptide antibiotics. Prospects of manipulating the antibacterial spectrum and combating acquired resistance. J. Biol. Chem. 1994, 269, 26107-26115.
19. Otvos, L. Jr.; Bokonyi, K.; Varga, I.; Otvos, B. I.; Hoffmann, R.; Ertl, H. C. J.; Wade, J. D.; McManus, A. M.; Craik, D. J.; Bulet, P. Insect peptides with improved protease-resistance protect mice against bacterial infection. Protein Sci. 2000, 9, 742-749.
20. Cudic, M.; Condie, B. A.; Weiner, D. J.; Lysenko, E. S.; Xiang, Z. Q.; O, I.; Bulet, P.; Otvos, L., Jr. Development of novel antibacterial peptides that kill resistant clinical isolates. Peptides 2002, 23, 271-283.
21. Cudic, M.; Lockatell, C. V.; Johnson, D. E.; Otvos, L., Jr. In vitro and in vivo activity of a designed antibacterial peptide analogue against uropathogens. Peptides 2003, 24, 807-820.
22. Otvos, L., Jr.; Snyder, C.; Condie, B.; Bulet, P.; Wade, J. D. Chimeric antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. 2005, 11, 29-42.
23. Otvos, L. The short, proline-rich antibacterial peptide family. Cell. Mol. Life Sci. 2002, 59, 1138-1150.
24. Cociancich, S.; Dupont, A.; Hegy, G.; Lanot, R.; Holder, F.; Hetru, C.; Hoffmann, J. A.; Bulet, P. Novel inducible antibacterial peptides from a hemipteran insect, the sap sucking-bug Pyrrhocoris apterus. Biochem. J. 1994, 300, 567-575.
25. Bulet, P.; Dimarcq, J.-L.; Hetru, C.; Lagueux, M.; Charlet, M.; Hegy, G.; van Dorsselaer, A.; Hoffmann, J. A. A novel inducible antibacterial peptide from Drosophila carries an O-glycosylated substitution. J. Biol. Chem. 1993, 268, 14893-14897.
26. Casteels, P.; Ampe, C.; Jacobs, F.; Vaeck, M.; Tempst, P. Apidaecins: antibacterial peptides from honeybees. EMBO J. 1989, 8, 2387-2391.
27. Bulet, P.; Urge, L.; Ohresser, S.; Hetru, C.; Otvos, L., Jr. Enlarged scale chemical synthesis and range of activity of drosocin, an O-glycosylated antibacterial peptide from Drosophila. Eur. J. Biochem. 1996, 238, 64-69.
28. Hoffmann, R.; Bulet, P.; Urge, L.; Otvos, L., Jr. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim. Biophys. Acta 1999, 1426, 459-467.
29. DiMarchi, R. D.; Neireiter, G. W.; Heath, W. F.; Gurd, F. R. Structural significance of the amino-terminal residues of sperm whale myoglobin. Biochemistry 1980, 19, 2454-2465.
30. Powell, M. F.; Grey, H.; Gaeta, F.; Sette, A.; Colon, S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharm. Sci. 1992, 81, 731-735.
31. Wong, H; Jia, L.; Camden, J. B.; Weitman, S. D. Liquid chromatography-mass spectrometry assay of a thiadiazole derivative in mice: application to pharmacokinetic studies. J. Chromatogr. 2001, 765, 55-62.
32. Weijzen, S.; Meredith, S. C.; Velders, M. P.; Elmishad, A. G.; Schreiber, H.; Kast, W. M. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J. Immunol. 2001, 166, 7151-7157.
33. Cudic, M.; Bulet, P.; Hoffmann, R.; Craik, D. J.; Otvos, L. Jr. Chemical synthesis, antibacterial activity and conformation of diptericin, an 82-mer peptide originally isolated from insects. Eur. J. Biochem. 2002, 266, 549-558.
34. Johnson, D. E.; Lockatell, C. V.; Russell, R. G.; Hebel, J. R.; Island, M. D.; Stapleton, A.; Stamm, W. E.; Warren, J. W. Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect. Immun. 1998, 66, 3059-3065.
35. Virella, G. Microbiology and infectious diseases; Williams and Wilkins: Philadelphia, 1997; pp 449-454.
36. Amsterdam, D. Susceptibility testing of antimicrobials in liquid media. In Antibiotics in Laboratory Medicine; Loman, V., Ed; Williams and Wilkins: Philadelphia, 1996; pp 52-111.
37. Mak, P.; Wojcik, K.; Silberring, J.; Dubin, A. Antimicrobial peptides derived from heme-containing proteins: hemocidins. Antonie Van Leeuwenhoek 2000, 77, 197-207.
38. Scott, M. G.; Davidson, D. J.; Gold, M. R.; Bowdish, D.; Hancock, R. E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 2002, 169, 3883-3891.
39. Hvidberg, H.; Struve, C.; Krogfelt, K. A.; Christensen, N.; Rasmussen, S. N.; Frimodt-Moller, N. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob. Agents Chemother. 2000, 44, 156-163.
40. Lupetti, A.; Welling, M. M.; Pauwels, E. K. J.; Nibbering, P. H. Radiolabeled antimicrobial peptides for infection detection. Lancet Infect. Dis. 2003, 3, 233-239.
41. Hui, L.; Leung, K.; Chen, H. M. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res. 2002, 22, 2811-2816.
42. Gura, T. Ancient system gets new respect. Science 2001, 291, 2068-2071.
43. Chen, J.; Falla, T. J.; Liu, H.; Hurst, M. A.; Fujii, C. A.; Mosca, D. A.; Embree, J. R.; Loury, D. J.; Radel, P. A.; Chang, C. C.; Gu, L.; Fiddes, J. C. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000, 55, 88-98.
44. Ge, Y.; MacDonald, D.; Henry, M. M.; Hait, H. I.; Nelson, K. A.; Lipsky, B. A.; Zasloff, M. A.; Holroyd, K. J. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis. 1999, 35, 45-53.
45. Navon-Venezia, S.; Feder, R.; Gaidukov, L.; Carmeli, Y.; Mor, A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 2002, 46, 689-694.
46. Otvos, L. Jr.; O, I.; Rogers, M. E.; Consolvo, P. J.; Condie, B. A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 2000, 39, 14150-14159.
47. Rothbard, J. B.; Kreider, E.; VanDeusen, C. L.; Wright, L.; Wylie, B. L.; Wender, P. A. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 2002, 45, 3612-3618.
48. Fernandez-Carneado, J.; Kogan, M. J.; Castel, S.; Giralt, E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of γ-zein. Angew. Chem., Int. Ed. 2004, 43, 1811-1814.
49. Chappie, D. S.; Hussein, R.; Joannou, C. L.; Hancock, R. E.; Odell, E.; Evans, R. W.; Siligardi, G. Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob. Agents Chemother. 2004, 48, 2190-2198.
50. Deslouches, B.; Phadke, S. M.; Lazarevic, V.; Cascio, M.; Islam, K.; Montelaro, R. C.; Mietzner, T. A. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob. Agents Chemother. 2005, 49, 316-322.
51. Gobbo, M.; Biondi, L.; Filira, F.; Gennaro, R.; Benincasa, M.; Scolaro, B.; Rocchi, R. Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin Ib analogues. J. Med. Chem. 2002, 45, 4494-4504.
52. McManus, A. M.; Otvos, L. Jr.; Hoffmann, R.; Craik, D. J. Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. Biochemistry 1999, 38, 705-714.
53. Rabel, D.; Charlet, M.; Ehret-Sabatier, L.; Cavicchioli, L.; Cudic, M.; Otvos, L., Jr.; Bulet P. Primary structure and in vitro antibacterial properties of the Drosophila melanogaster attacin C Pro-domain. J. Biol. Chem. 2004, 279, 14853-14859.
54. Haversen, L. A.; Engberg, I.; Baltzer, L.; Dolphin, G.; Hanson, L. A.; Mattsby-Baltzer, I. Human lactoferricin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 2000, 68, 5816-5823.
55. Henry, D. C., Jr.; Bettis, R. B.; Riffer, E.; Haverstock, D. C.; Kowalsky, S. F.; Manning, K.; Hamed, K. A.; Church, D. A. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin. Ther. 2002, 24, 2088-2104.
56. Norris, C. R.; Williams, B. J.; Ling, G. V.; Franti, C. E.; Johnson, D. L.; Ruby, A. L. Recurrent and persistent urinary tract infections in dogs: 383 cases (1969-1995). J. Am. Anim. Hosp. Assoc. 2000, 36, 484-492.
57. Ling, G. V.; Ruby, A. L. Gentamicin for treatment of resistant urinary tract infections in dogs. J. Am. Vet. Med. Assoc. 1979, 175, 480-481.
58. Cohn, L. A.; Gary, A. T.; Fales, W. H.; Madsen, R. W. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J. Vet. Diagn. Invest. 2003, 15, 338-343.
59. Cooke, C. L.; Singer R. S.; Jang, S. S.; Hirsh, D. C. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J. Am. Vet. Med. Assoc. 2002, 220, 190-192.
60. Fields, G. B.; Noble, R. L. Solid-phase peptide synthesis using 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.